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406 LETTERS TO THE EDITORPolygenic risk score for atopic
dermatitis in the Canadian populationTo the Editor:
Atopic dermatitis (AD) is characterized by a damaged skin
barrier that allows allergens to penetrate the body, leading to
sensitization and a higher risk of developing food allergies
(relative risk [RR], 33.79), asthma (RR, 7.04), and/or rhinitis
(RR, 11.75), all features of the atopic march.1 Recent evidence
has shown that the atopic march can be modified in high-risk
infants with early interventions directed at reestablishing
and/or maintaining skin barrier function with intense use of
simple emollients, and introducing food allergens early into
the diet.2-5 Although these constitute examples of low-
intensity, high-impact interventions for health care systems,
their successful and indiscriminate implementation in the whole
population is neither feasible nor realistic. In this context,
building a predictive tool to identify children at high risk of
developing moderate to severe AD (MSAD) would allowFIG 1. Receiver-operating characteristic (ROC) curves
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ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).targeted interventions with maximized impact. In this study, a
polygenic risk score (PRS) with an area under the curve
(AUC) of 88% and explaining 37% of MSAD variance was
established for the Canadian population.
Two scenarios for PRS were tested, one using genome-wide
association study (GWAS) loci identified through existing
literature and the other based on the strongest GWAS hits found
in 2 Canadian cohorts (see Table E1 in this article’s Online
Repository at www.jacionline.org; for the detailed methodology,
see this article’s Methods section in the Online Repository at
www.jacionline.org).
The first scenario evaluated whether the best associations in the
literature were suitable to build a PRS for AD with a good
discriminative value in a specific population. The 25 best
associations documented in GWASs of AD (see Tables E2 and
E3 in this article’s Online Repository at www.jacionline.org)
were selected. For each of these, a region spanning 6100 kb
was tested for the best associated genetic variant with MSAD
(for clinical definitions, see this article’s Online Repository atand AUCs for the PRSs of MSAD, calculated for
ature (A), and in 2 Canadian cohorts (C), along with
r both PRSs in (B) and (D). Dark lines represent the
e lines for those with them.
FIG 2. Receiver-operating characteristic (ROC) curves and AUCs for diseases in the atopic march: MSAD
(black), food allergies (blue), asthma (orange), and rhinitis (green). The PRS was calculated from the 25 best
genome-wide associations in the training cohort for the model without (A) and with (B) covariates, and in
the testing cohort for the model without (C) and with (D) covariates. Finally, a model using the binary
variable derived from the PRSwas run in the testing cohort for themodel without (E) and with (F) covariates.
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from the 2 Canadian cohorts (training cohort, n 5 2688
individuals; see Fig E1 in this article’s Online Repository at
www.jacionline.org) using a general regression model to extract
risk alleles and b estimates (5 ln[odds ratio]).E7 The PRS was
then built for each individual of the training and testing groups
(the remaining 20% of individuals; n 5 676) considering the
number of risk alleles from genetic variants weighted by their b
estimates. The discriminative value of PRS was assessed by a
receiver-operating characteristic curve analysis and gave an
AUC of 71% (Fig 1, A). According to Nagelkerke’s pseudo-R2,
11% of MSAD variance was explained by PRS.
Once covariates were added to the model (sex, age, and parents’
ethnicity), an AUC of 86% was reached (Fig 1, A) and
the model explained 31% of MSAD variance. These results
highlight the dependence of the first scenario upon covariates to
reach a good discriminative value (AUC between 80% and
89%).E12
The second scenario took advantage of 2 Canadian cohorts to
build another PRS based on the best associations for AD in the
Canadian population, which is ethnically diverse. The
Saguenay–Lac-Saint-Jean asthma familial cohortE1 includes
individuals of French descent from this region in northern
Quebec, Canada, and the CHILD cohort studyE2 comprises
both those of English descent and those of multiple other
origins living in British Columbia (Vancouver), Alberta
(Edmonton), Manitoba (Winnipeg, Morden, and Winkler),
and Ontario (Toronto). Each site obtained local Research Ethics
Board approval for the study, and each participating parent
gave signed informed consent. The GWAS was performed on
the training cohort using the Multiple Family-based
Quasi-Likelihood Score (MFQLS) test,E10 and a PRS was built
with the 25 best associations (see Table E4 and Fig E1 in this
article’s Online Repository at www.jacionline.org) after
running a general regression model to extract their b estimates.
The PRS obtained had an AUC of 85% (Fig 1, C) and explained
33% of MSAD variance. Adding the same covariates as for the
first scenario, the AUC was 88% (Fig 1, C), corresponding to a
sensitivity and specificity of both 84%, and the PRS explained
37% of MSAD variance. The 2 models of this second scenario
demonstrate a good discriminative value.E12 In comparison,
AUCs derived from PRSs in the literature range from 53% to
76%,6 and show relatively low percentages of explained
variance (0.3% for brain tumor compared with 36% in this
study).7 The PRS based on the Canadian cohorts also carried
good predictive values for other allergic phenotypes (for
clinical definitions, see this article’s Online Repository at
www.jacionline.org), with AUCs of 75% for food allergies,
71% for asthma, and 69% for allergic rhinitis (Fig 2, A and
B). Interestingly, the discriminative value for asthma was
similar than that reported using the Predicting Asthma Risk
in Children clinical tool, based on respiratory symptoms
occurring before school age (AUC 5 77%), even though the
predictive tool proposed in this study is designed to identify
children at high risk of developing MSAD and not directly to
detect those at high risk of developing asthma.8 Results were
validated in the testing cohort, with AUCs of 85% and 93%
for the models for MSAD without and with covariates,
respectively (with 31% and 49% of explained variability) and
AUCs of 75%, 75%, and 77% for food allergies, asthma, and
rhinitis (Fig 2, C and D).These results demonstrate that the second scenario, which used
data from the targeted population to build the PRS, best explains
the risk of developing MSAD even without considering any
covariate. It is interesting to note that no locus was
common between the 25 best associations from the 2 scenarios
(Tables E2-E4). It confirms the need to characterize the genetic
profile of each specific population before building a PRS in order
to reach a good discriminative value.
To be an efficient predictive tool, a cutoff value has to be
established to distinguish between low- and high-risk
individuals. When examining the progression of risk to
develop MSAD on the basis of individuals’ PRSs from the
second scenario, there is a clear inflection in the curve at the 9th
decile (OR, 17.5, compared with the first decile) with further
progressing up to the 10th decile (OR, 39.0; Fig 1, D; see Table
E5 in this article’s Online Repository at www.jacionline.org).
In contrast, risk progression was much more continuous with
PRSs calculated from the first scenario, which is further evi-
dence of its lower discriminative value (Fig 1, B, and Table
E5). Using a binomial logistic regression with the above-
mentioned covariates in the training cohort, being classified
as high risk (defined as having a PRS between the 9th and
10th deciles) was strongly associated with the risk of devel-
oping AD (odds ratio [OR], 2.96; P 5 2.62 3 10207), MSAD
(OR, 11.73; P 5 1.27 3 10221), food allergies (OR, 5.80;
P 5 2.96 3 10219), asthma (OR, 3.96; P 5 2.12 3 10210),
and rhinitis (OR, 2.29; P 5 .001; see Table E6 in this article’s
Online Repository at www.jacionline.org). For comparison, a
PRS built from 4 selected genes (GSTP1, TNF, TLR2, and
TLR4) was previously reported to have an OR of only 1.22
for AD.9 Analyses in the testing cohort also gave significant re-
sults for MSAD (OR, 5.67; P5 .001), food allergies (OR, 3.27;
P 5 .003), and asthma (OR, 3.15; P 5 .013) even though the
cohort used was smaller. Moreover, AUCs for the binary PRS
in the testing cohort had similar values than for the continuous
PRS (Fig 2, E and F). These are interesting results for clinical
applications because such a predictive tool based on only 25
genetic variants and basic covariates available at birth could
be easily added to the test routines already established in
Canada, which are performed on blood samples collected by
a prick on the heels of newborns.
Finally, to test whether a smaller number of genetic variants can
be as efficient, a PRS was tested for genetic variants from the
second scenario that were associated with P less than 1 3 10210
(n 5 8). The discriminative value was well preserved with a
corresponding AUC of 86% (Fig E2). However, analyses using
a cutoff value to identify children at high risk of developing
MSAD in the testing cohort gave less interesting results than
the ones for the PRS built from 25 genetic variants, showing a
greater dependence on covariates (AUC for the model without
covariates 5 67% and with covariates 5 92%).
To conclude, the use of 2 independent multiethnic Canadian
cohorts allowed development of a PRS with an AUC of 88%
and explaining 37% of MSAD variance. Considering the
accumulating body of evidence indicating the need to intervene
early to prevent the development of AD and associated
allergic comorbidities, discriminative PRS such as this one
could prove helpful to guide interventions and direct
investments toward those patients most likely to benefit,
ensuring the cost-effectiveness and sustainability of early
prevention programs.
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https://doi.org/10.1016/j.jaci.2020.04.057Eosinophilic esophagitis with
extremely high esophageal eosinophil
countsTo the Editor:
Eosinophilic esophagitis (EoE) is an inflammatory disease
characterized by eosinophil infiltration into the esophageal
mucosa, with a peak count of at least 15 eosinophils per hpf
following endoscopic biopsy. However, the range of esophageal
eosinophilia can vary markedly from patient to patient. A key
question in the field is to understand the relationship of eosinophil
levels with disease features, especially because eosinophil-
targeted therapies are now available. Patients with extremely
high levels of esophageal eosinophilia have not previously been
studied. It is unknown whether these patients exhibit
characteristics different from those of patients with EoE who
have esophageal eosinophilia that is near the threshold of disease
diagnosis. Given this fact, we aimed to establish whether any
significant clinical, endoscopic, histologic, or transcriptomic
features differ between patients with extremely high levels of
esophageal eosinophilia and those with levels near the threshold
of disease diagnosis.
Among those in a registry of patients with EoE, we identified
the group of patients with the highest recorded levels of
esophageal eosinophilia (>350 eosinophils per hpf), referred to
as EoE-High. We subsequently identified a second group that had
relatively low levels of esophageal eosinophilia (15-24
eosinophils per hpf), referred to as EoE-Low. There were 74
patients in the registry with eosinophil counts of 15 to 24
eosinophils per hpf on a distal esophageal biopsy specimen.
A random number generator was used to select the 14 patients
comprising the EoE-Low group. Phenotypic and clinical
characteristics were gathered on the basis of electronic medical
records and detailed questionnaires as part of a research registry.
Endoscopic characteristics were assessed on the basis of findings
from esophagogastroduodenoscopy operative reports. Histologic
characteristics were classified on the basis of the histology
scoring system.1 Molecular analysis was performed by using
the 96-gene EoE diagnostic panel.2 Age, demographics,
esophageal eosinophil levels, absolute eosinophilia, IgE levels,
atopic comorbidities, and treatment modalities were assessed.
Study population characteristics are summarized in Table E1
(in this article’s Online Repository at www.jacionline.org). At
the time of biopsy, the EoE-Low group was younger than the
EoE-High group, with mean ages of 6.3 6 3.4 years and
13.4 6 10.3 years, respectively (P 5 .02). The EoE-High group
had a disease duration significantly longer than that in the
